Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers

NCT02934464 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

280

Enrollment

OTHER

Sponsor class

Conditions

Stomach Neoplasms

Interventions

DRUG: RAMUCIRUMAB
DRUG: Paclitaxel
DRUG: FOLFOX 4
DRUG: mFOLFOX 6
DRUG: XELOX

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano